Literature DB >> 18692537

An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Chandra Shekhar Bakshi1, Meenakshi Malik, Manish Mahawar, Girish S Kirimanjeswara, Karsten R O Hazlett, Lance E Palmer, Martha B Furie, Rajendra Singh, J Andres Melendez, Timothy J Sellati, Dennis W Metzger.   

Abstract

Vaccination of mice with Francisella tularensis live vaccine strain (LVS) mutants described so far have failed to induce protection in C57BL/6 mice against challenge with the virulent strain F. tularensis SchuS4. We have previously reported that a mutant of F. tularensis LVS deficient in iron superoxide dismutase (sodB(Ft)) is hypersensitive to oxidative stress and attenuated for virulence in mice. Herein, we evaluated the efficacy of this mutant as a vaccine candidate against respiratory tularemia caused by F. tularensis SchuS4. C57BL/6 mice were vaccinated intranasally (i.n.) with the sodB(Ft) mutant and challenged i.n. with lethal doses of F. tularensis SchuS4. The level of protection against SchuS4 challenge was higher in sodB(Ft) vaccinated group as compared to the LVS vaccinated mice. sodB(Ft) vaccinated mice following SchuS4 challenge exhibited significantly reduced bacterial burden in lungs, liver and spleen, regulated production of pro-inflammatory cytokines and less severe histopathological lesions compared to the LVS vaccinated mice. The sodB(Ft) vaccination induced a potent humoral immune response and protection against SchuS4 required both CD4 and CD8 T cells in the vaccinated mice. sodB(Ft) mutants revealed upregulated levels of chaperonine proteins DnaK, GroEL and Bfr that have been shown to be important for generation of a potent immune response against Francisella infection. Collectively, this study describes an improved live vaccine candidate against respiratory tularemia that has an attenuated virulence and enhanced protective efficacy than the LVS.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692537      PMCID: PMC2652725          DOI: 10.1016/j.vaccine.2008.07.051

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  52 in total

1.  Studies with tularemia vaccines in volunteers. IV. Brucella aggiutinins in vaccinated and nonvaccinated volunteers challenged with Pasteurella tularensis.

Authors:  S SASLAW; H N CARLISLE
Journal:  Am J Med Sci       Date:  1961-08       Impact factor: 2.378

2.  Aerogenic immunization of man with live Tularemia vaccine.

Authors:  R B Hornick; H T Eigelsbach
Journal:  Bacteriol Rev       Date:  1966-09

3.  OxyR, a positive regulator of hydrogen peroxide-inducible genes in Escherichia coli and Salmonella typhimurium, is homologous to a family of bacterial regulatory proteins.

Authors:  M F Christman; G Storz; B N Ames
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

4.  Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen.

Authors:  J Wayne Conlan; Hua Shen; Ann Webb; Malcolm B Perry
Journal:  Vaccine       Date:  2002-10-04       Impact factor: 3.641

5.  Inactivated Francisella tularensis live vaccine strain protects against respiratory tularemia by intranasal vaccination in an immunoglobulin A-dependent fashion.

Authors:  Shawn D Baron; Rajendra Singh; Dennis W Metzger
Journal:  Infect Immun       Date:  2007-02-12       Impact factor: 3.441

6.  Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.

Authors:  J Wayne Conlan; Hua Shen; Rhonda Kuolee; Xigeng Zhao; Wangxue Chen
Journal:  Vaccine       Date:  2005-03-31       Impact factor: 3.641

7.  Passive protection of mice against lethal Francisella tularensis (live tularemia vaccine strain) infection by the sera of human recipients of the live tularemia vaccine.

Authors:  J J Drabick; R B Narayanan; J C Williams; J W Leduc; C A Nacy
Journal:  Am J Med Sci       Date:  1994-08       Impact factor: 2.378

Review 8.  Animal models of Francisella tularensis infection.

Authors:  C Rick Lyons; Terry H Wu
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

9.  Increased synthesis of DnaK, GroEL, and GroES homologs by Francisella tularensis LVS in response to heat and hydrogen peroxide.

Authors:  M Ericsson; A Tärnvik; K Kuoppa; G Sandström; A Sjöstedt
Journal:  Infect Immun       Date:  1994-01       Impact factor: 3.441

10.  Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica.

Authors:  Stephan Stenmark; Helena Lindgren; Arne Tärnvik; Anders Sjöstedt
Journal:  Microb Pathog       Date:  2003-08       Impact factor: 3.738

View more
  55 in total

1.  A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.

Authors:  Qingmei Jia; Bai-Yu Lee; Richard Bowen; Barbara Jane Dillon; Susan M Som; Marcus A Horwitz
Journal:  Infect Immun       Date:  2010-07-19       Impact factor: 3.441

2.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

Review 3.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

4.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

5.  Bronchus-associated lymphoid tissue (BALT) and survival in a vaccine mouse model of tularemia.

Authors:  Damiana Chiavolini; Javier Rangel-Moreno; Gretchen Berg; Kate Christian; Laura Oliveira-Nascimento; Susan Weir; Joseph Alroy; Troy D Randall; Lee M Wetzler
Journal:  PLoS One       Date:  2010-06-16       Impact factor: 3.240

6.  Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.

Authors:  Hua Shen; Gregory Harris; Wangxue Chen; Anders Sjostedt; Patrik Ryden; Wayne Conlan
Journal:  PLoS One       Date:  2010-10-12       Impact factor: 3.240

7.  FeoB-mediated uptake of iron by Francisella tularensis.

Authors:  Cindy A Thomas-Charles; Huaixin Zheng; Lance E Palmer; Patricio Mena; David G Thanassi; Martha B Furie
Journal:  Infect Immun       Date:  2013-05-28       Impact factor: 3.441

Review 8.  Working toward the future: insights into Francisella tularensis pathogenesis and vaccine development.

Authors:  Roger D Pechous; Travis R McCarthy; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2009-12       Impact factor: 11.056

9.  Mucosal immunotherapy for protection from pneumonic infection with Francisella tularensis.

Authors:  Ryan M Troyer; Katie L Propst; Jeff Fairman; Catherine M Bosio; Steven W Dow
Journal:  Vaccine       Date:  2009-05-31       Impact factor: 3.641

10.  Epitope-based vaccination against pneumonic tularemia.

Authors:  Stephen H Gregory; Stephanie Mott; Jennifer Phung; Jinhee Lee; Leonard Moise; Julie A McMurry; William Martin; Anne S De Groot
Journal:  Vaccine       Date:  2009-07-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.